
Century Therapeutics, Inc.: updates and filings
Price
$1.65
November 13, 2026Market cap $297M
What Ploutos Investor adds for Century Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 12, 2026Results of operationsForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 2, 2026Regulation FD disclosure, other material eventsForm8-K
- Sep 9, 2026Officer or director change, Regulation FD disclosureForm8-K
- Aug 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jun 16, 2026Officer or director changeForm8-K
- Jun 12, 2026Amended articles or bylaws, shareholder voteForm8-K
- Jun 8, 2026Other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 13, 2026Results of operationsForm8-K
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 27, 2026Additional annual meeting materialFormDEFA14A
- Apr 27, 2026Annual meeting proxy statementFormDEF 14A
- Apr 16, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 16, 2026Preliminary proxy statementFormPRE 14A
- Mar 26, 2026Other material eventsForm8-K
- Mar 12, 2026Shares registered for employeesFormS-8
- Mar 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Mar 12, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 17, 2026FilingFormEFFECT
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 17, 2026Letter from the SECFormUPLOAD
- Feb 17, 2026Correspondence with the SECFormCORRESP
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 2, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Sep 9, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Aug 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jun 16, 2026 | 8-K | Officer or director change | Document |
| Jun 12, 2026 | 8-K | Amended articles or bylaws, shareholder vote | Document |
| Jun 8, 2026 | 8-K | Other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 27, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 27, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 16, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 16, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Mar 26, 2026 | 8-K | Other material events | Document |
| Mar 12, 2026 | S-8 | Shares registered for employees | Document |
| Mar 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Mar 12, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 17, 2026 | EFFECT | Filing | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 17, 2026 | UPLOAD | Letter from the SEC | Document |
| Feb 17, 2026 | CORRESP | Correspondence with the SEC | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 15, 2021.
The full analysis
What do Century Therapeutics's filings show?
The filings are where every one of Century Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.